15/11/2024  20:29:09 Diferencia -5.2000 Volumen Bid- Ask- Capitalización de mecado Dividendo A. P/E Ratio
308.3000USD -1.66% 1,051
Volumen de negocios: 329,963.9000
-Volumen de oferta: - -Tamaño/ Volumen/ Formato de Ask: - 265.38 mil millonesUSD - -

Descripción de negocio

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
 

Consejo de gestión & Consejo de supervisión

CEO
Dr. Thomas Schinecker
Consejo de gestión
Dr. Alan Hippe, Cristina A. Wilbur, Teresa Graham, Matt Sause , Claudia Bockstiegel, Prof. Dr. Hans Clevers, Dr. Levi Garraway, Silke Hornstein, Dr. Aviv Regev, Barbara Schädler, Boris L. Zaïtra
Consejo de supervisión
Dr. Severin Schwan, André Hoffmann, Anita Hauser, Dr. Claudia Süssmuth Dyckerhoff, Dr. Patrick Frost, Prof. Dr. Richard Lifton, Dr. Mark Schneider, Dr. Jemilah Mahmood, Prof. Dr. Akiko Iwasaki, Dr. Jörg Duschmalé
 

Datos de la empresa

Nombre: Roche Holding
Dirección: Grenzacherstraße 124,CH-4070 Basel
Teléfono: +41-61-688-1111
Fax: -
E-mail: basel.webmaster@roche.com
Internet: www.roche.com
Industria: Healthcare
Sector: Pharmaceutical Industry
Subsector: Pharmaceuticals
Fin del año financiero: 31/12
Acciones de libre circulación: 88.00%
Fecha de OPI: 03/04/1995

Relación con inversores

Nombre: Bruno Eschli
IR teléfono: +41 (61) 687 5284
IR-fax: +41 (61) 691 0014
IR e-mail: bruno.eschli@roche.com

Calendario de la empresa

CW 5 | 30/01/2025 4th Quarter/Annual Report
 

Accionistas mayoritarios

Aktionärsgruppe der Familien Hoffmann und Oeri-Hoffmann
 
67.50%
FreeFloat
 
24.92%
Maja Oeri
 
7.58%